Recently, immune checkpoint‐modulating agents (represented by anti‐CTLA4 and anti‐PD antibodies), CAR‐T cells, and neoantigen vaccines have been seen to be successful in enhancing the antitumor effect in numerous types of cancer, bringing a paradigm shift to cancer treatment.72, 73, 74, 75. This evidence concerns the gene CTLA4 and cancer.